Results 91 to 100 of about 801 (115)

Dopamine, Cognitive Impairments and Second-Generation Antipsychotics: From Mechanistic Advances to More Personalized Treatments

Pharmaceuticals, 2020
Salvatore Salomone, Francesco Papaleo, Sebastiano Alfio Torrisi   +2 more
exaly  

The effect of first- and second-generation antipsychotics on brain morphology in schizophrenia: A systematic review of longitudinal magnetic resonance studies with a randomized allocation to treatment arms

Journal of Psychopharmacology, 2022
Konstantinos Fountoulakis
exaly  

Tardive dyskinesia risk with first‐ and second‐generation antipsychotics in comparative randomized controlled trials: a meta‐analysis

World Psychiatry, 2018
Christoph Correll, Kane Jm, Stefan Leucht   +2 more
exaly  

Second-Generation Antipsychotics and Dysregulation of Glucose Metabolism: Beyond Weight Gain

Cells, 2019
Vitor Ferreira, Diana Grajales, Angela Martinez Valverde   +2 more
exaly  

New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis

Lancet, The, 2003
Johannes Hamann, Stefan Leucht, KRISTIAN Wahlbeck   +2 more
exaly  

Second-Generation Antipsychotics (SGAs)

2021
openaire   +1 more source

Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis

International Journal of Neuropsychopharmacology, 2013
Christoph Correll, Jian-Ping Zhang, Delbert Robinson   +2 more
exaly  

Second-Generation Antipsychotics

2015
openaire   +1 more source

Second-Generation Antipsychotics for Bipolar Depression

Only five atypical antipsychotics are FDA-approved for bipolar depression—cariprazine, lumateperone, lurasidone, olanzapine-fluoxetine, and quetiapine. Among them, only cariprazine and quetiapine also treat mania. When starting lumateperone for bipolar depression, consider initiating at a lower dose than the recommended 42 mg treating dose, as clinical
openaire   +1 more source

Clinically relevant interactions between newer antidepressants and second-generation antipsychotics

Expert Opinion on Drug Metabolism and Toxicology, 2014
Edoardo Spina, JOSÉ De Leon
exaly